ClinicalTrials.gg
RecruitingNCT07298395Updated Sep 25, 2026

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of ENV-294 and Placebo in Atopic Dermatitis (AD), sponsored by Enveda Therapeutics. Recruiting at 32 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Enveda Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Sep 25, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
257th of 544
105 · median 96
Started
2025
with 40 others
Phase 2
202 of 639
18 open now
Primary completion
2026-12
later than 28 of 115 live
Registered
615th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 257th largest by planned enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 202 in phase 2, reaches primary completion later than 28 of the 115 other live ones, and was the 615th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.

The main questions it will answer are:

  • Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294
  • What medical problems do participants have when taking ENV-294

Participants will:

  • Take drug ENV-294 or a placebo once every day for 12 weeks
  • Visit the clinic every 2 to 4 weeks for checkups and tests
  • Keep a diary of their symptoms and when they took their study drug
  • Return to the clinic for the final study visit at approximately week 16
03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit
  • Have moderate-to-severe AD at screening and baseline as defined by the following criteria:

    • A vIGA score of 3 (moderate) or 4 (severe)
    • EASI score of ≥16
    • BSA ≥10%
    • PP-NRS score of ≥4
  • Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as ) within the past 6 months
  • Use a bland moisturizer at least daily

Exclusion criteria

Exclusion Criteria:

  • Current or recurrent medical conditions that could affect the study drug or study assessments
  • Any illness that could impact participant safety or active infections
  • Ongoing skin condition or large tattoos that would interfere with clinical assessment
  • skin infection requiring treatment
  • Clinically significant abnormal laboratory assessments at screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    ENV-294 Treatment Arm

    ENV-294 will be administered to those participants randomized to the treatment arm.

    Drug: ENV-294

  • Placebo comparator
    Placebo Arm

    A placebo will be administered to those participants randomized to the placebo arm.

    Drug: Placebo

Interventions

  • ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.

  • DrugPlacebo

    Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of ENV-294 compared to placebo on severity and extent of atopic dermatitis (AD)

    The effectiveness of ENV-294 compared with placebo will be assessed by the percent change in Eczema Area and Severity Index (EASI) score from the start of the study (Baseline) to Week 12 (Day 85). The EASI score measures the extent and severity of atopic dermatitis, with higher scores indicating more severe disease.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Incidence and Severity of Adverse Events

    Number and seriousness of adverse events (AEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug.

    Time frame: Baseline to Week 12

  2. EASI-75 Response

    Percentage of participants with at least 75% reduction from Baseline in Eczema Area and Severity Index (EASI) score.

    Time frame: Baseline to Week 12

  3. vIGA Response

    Proportion of participants who achieve a ≥2-point reduction from Baseline in validated Global Investigator Assessment (vIGA) score and a score of 0 or 1.

    Time frame: Baseline to Week 12

  4. Patient-Reported Outcomes

    Change and percent change in Peak Pruritus Numerical Rating Scale (PP-NRS).

    Time frame: Baseline to Week 12

  5. Patient-Reported Outcomes

    Change and percent change in Patient Oriented Eczema Measure (POEM).

    Time frame: Baseline to Week 12

  6. Pharmacokinetics of ENV-294

    Observed concentration values of ENV-294 at the times blood samples are collected.

    Time frame: Baseline to Week 12

07

Study locations

32 of 32 sites recruiting
  • Enveda Investigative Site
    Birmingham, Alabama 35244, United States
    Recruiting
  • Enveda Investigative Site
    Hot Springs, Arkansas 71913, United States
    Recruiting
  • Enveda Investigative Site
    Beverly Hills, California 90212, United States
    Recruiting
  • Enveda Investigative Site
    Fremont, California 94538, United States
    Recruiting
  • Enveda Investigative Site
    San Diego, California 92121, United States
    Recruiting
  • Enveda Investigative Site
    San Diego, California 92123, United States
    Recruiting
  • Enveda Investigative Site
    Santa Monica, California 90403, United States
    Recruiting
  • Enveda Investigative Site
    West Hills, California 91307, United States
    Recruiting
  • Enveda Investigative Site
    Fort Lauderdale, Florida 33308, United States
    Recruiting
  • Enveda Investigative Site
    Miami, Florida 33175, United States
    Recruiting
  • Enveda Investigative Site
    Miramar, Florida 33027, United States
    Recruiting
  • Enveda Investigative Site
    Atlanta, Georgia 30327, United States
    Recruiting
  • Enveda Investigative Site
    Chicago, Illinois 60657, United States
    Recruiting
  • Enveda Investigative Site
    Clarksville, Indiana 47129, United States
    Recruiting
  • Enveda Investigative Site
    New Albany, Indiana 47150, United States
    Recruiting
  • Enveda Investigative Site
    West Lafayette, Indiana 47906, United States
    Recruiting
  • Enveda Investigative Site
    Louisville, Kentucky 40217, United States
    Recruiting
  • Enveda Investigative Site
    Louisville, Kentucky 40241, United States
    Recruiting
  • Enveda Investigative Site
    Auburn Hills, Michigan 48326, United States
    Recruiting
  • Enveda Investigative Site
    Bay City, Michigan 48706, United States
    Recruiting
  • Enveda Investigative Site
    Clinton Township, Michigan 48038, United States
    Recruiting
  • Enveda Investigative Site
    Warren, Michigan 48088, United States
    Recruiting
  • Enveda Investigative Site
    Las Vegas, Nevada 89145, United States
    Recruiting
  • Enveda Investigative Site
    New York, New York 10029, United States
    Recruiting
  • Enveda Investigative Site
    Wilmington, North Carolina 28405, United States
    Recruiting
  • Enveda Investigative Site
    Canton, Ohio 44718, United States
    Recruiting
  • Enveda Investigative Site
    Mayfield Heights, Ohio 44124, United States
    Recruiting
  • Enveda Investigative Site
    Camp Hill, Pennsylvania 17011, United States
    Recruiting
  • Enveda Investigative Site
    Arlington, Texas 76011, United States
    Recruiting
  • Enveda Investigative Site
    Houston, Texas 77004, United States
    Recruiting
  • Enveda Investigative Site
    San Antonio, Texas 78218, United States
    Recruiting
  • Enveda Investigative Site
    Norfolk, Virginia 23502, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Dec 22, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
60→105
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Enrollment 60→105
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07298395
Lead sponsor
Enveda Therapeutics
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Dec 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 25, 2026

Study contacts

Clinical Operations
Contact
env-294.clinicaltrials@enveda.com
Gurpreet Ahluwalia, PhD
study director · Enveda Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ENV-294

Start the discussion